Q3 2026 Vanda Pharmaceuticals Inc. Earnings Conference Call - VANDA PHARMACEUTICALS INC

Explicit Guidance:

• FY2026 Revenue: Expects total revenues from FNAPT, Bisanti, Hetlios, Ponvori, and Nereus to exceed $240 million.
• FY2026 Nereus Revenue: Expects Nereus revenue to be less than $10 million for the full year due to early-stage growth and awareness ramp-up.
• Cash Burn: Not providing specific 2026 cash guidance; expects 2026 Cash Burn to be greater than 2025 Cash Burn due to ongoing Phase III programs and launch preparations.
• Operating Expenses (OpEx): OpEx decreased 18% QoQ in Q3 2026 to $93.3 million; expects OpEx to decrease further in future quarters as Phase 3 and launch preparation activities conclude.
• Tax Rate: Tax expense expected to be nominal going forward, pending the removal of the valuation allowance on deferred tax assets.

Business-Segment Outlook:

• FNAPT: Continued strong momentum; new-to-brand (NBRX) prescriptions up 18% YoY in Q3 2026; TRX up 25% YoY and 72% since Bipolar I approval (Q2 2024).
• Bisanti: FDA approved for Bipolar I and Schizophrenia; commercial launch expected in Q4 2026 (likely before end of Q4). Protected by data exclusivity through Feb 20, 2031, with patents expiring May 31, 2044.
• Nereus: Launched Q2 2026; Q3 2026 saw >100% growth in TRX and unique prescribers vs Q2. Product is "promotionally sensitive" with strong DTC channel performance. Target patient profile includes those starting/restarting GLP-1 therapy or escalating doses.
• Hetlios: Net sales impacted by specialty pharmacy inventory cycles; expects potential significant decline in future periods due to generic competition, despite remaining market share leader.
• Ponvori: Revenue subject to variable consideration dispute (~$3M recognized in Q4 2024).
• Dysante (MDD): Phase 3 study ongoing; expects results in H1 2027. Enrolled 55% of 500-patient target across 54 US/EU sites.
• Product Mix: Anticipates 6 approved products by end of 2026 (FNAPT, Bisanti, Hetlios, Ponvori, Nereus, Quimilza pending).

Market and Competitive Outlook:

• FNAPT vs. Bisanti Transition: Expects to break out revenues for FNAPT and Bisanti post-launch. Anticipates a gradual patient switch from FNAPT to Bisanti taking 3–4 months post-launch to see quantifiable results; expects to capture new patient starts and existing FNAPT patients switching.
• GPP Market (Quimilza): Emerging market with increasing diagnosis rates; estimated several thousand patients in the US, most untreated.
• GLP-1 Market (Nereus): Label expansion to GLP-1 induced vomiting expected to target patients during titration phases or dose escalation; not expected to be chronic maintenance but acute preventive use (few days pre/post-injection).
• Pricing Strategy: Nereus cash price set at WAC $255 with 67% discount for cash/govt customers; philosophy prioritizes access and payer footprint expansion for GLP-1 indication.

Macro / Industry Outlook:

• Regulatory Milestones:
  • Quimilza (GPP): PDUFA target date December 12, 2026.
  • Nereus (GLP-1): Plan to submit Supplemental New Drug Application (sNDA) following positive Phase 3 results; expects FDA discussion prior to filing.
  • Hetlios (DSW-PD): Plan to submit sNDA following positive Phase 3 results; potential first-in-class approval.
  • Hetlios (Jet Lag): Administrative hearing before ALJ scheduled Dec 14–18, 2027.
• Legal Challenges: Pursuing litigation against FDA refusal for Hetlios (insomnia) and Nereus (gastroparesis); Nereus briefing due mid-November; Hetlios insomnia case awaiting DC Circuit decision post-Sept 2026 oral argument.

Strategic Initiatives:

• Launch Preparations: Manufacturing commercial supplies for Bisanti, Nereus, and Quimilza; expecting to be ready for Bisanti market entry in Q4 2026.
• Commercial Infrastructure: Expanded sales force for FNAPT to ~300 representatives in H2 2025; face-to-face calls up 35% YoY in first nine months of 2026.
• Pipeline Development: Considering PK bridging proposal to FDA for Iloperidone LAI program due to slow recruitment and low relapse rates in placebo groups.
• Quimilza Launch Timeline: Goal to launch in first half of 2027 if approved Dec 12, 2026.

Risks and Headwinds to Outlook:

• Generic Competition: Continued erosion of Hetlios revenue due to US generic competition; potential for significant decline in future periods.
• Inventory Volatility: Nereus and Hetlios revenues subject to variability due to specialty pharmacy and wholesaler inventory stocking levels (revenue recognition constraints on probable reversals).
• Regulatory Uncertainty: FDA approval timelines for Quimilza, Nereus (sNDA), and Hetlios (sNDA) are contingent on review processes; legal outcomes for Jet Lag and Gastroparesis indications remain uncertain.
• Clinical Trial Variability: Nereus Phase 3 showed reduced efficacy (27% reduction) vs Phase 2 (50%) on primary endpoint due to patient/site variability, though robust in severe cases.
• Cash Burn: Expect increased operating expenses in 2025/2026 compared to prior years; cash burn projected to increase in 2026.
• Variable Consideration: Potential revenue recognition issues regarding Ponvori variable consideration.

Management Tone on the Future:

• Confidence: Strong confidence in the "moderating costs and driving revenue growth" strategy; optimistic about sustainable long-term value and "strong market response" to commercial activities.
• Cautious Optimism on Nereus: Acknowledges early growth is "likely to progress slower" and revenue will be < $10M for FY2026, but views "early signs as encouraging."
• Cost Discipline: Confident that OpEx will decrease further as specific high-cost activities (Phase 3, launch prep) conclude.
• Transition Strategy: Patient approach to the FNAPT-to-Bisanti transition, acknowledging 90-day prescription dynamics will slow immediate switches.

Miscellaneous:

• Tax Event: One-time non-cash income tax charge established in Q4 2025; resulted in nominal tax expense expected going forward.
• Milestone Payments: $10 million paid to Eli Lilly in Q1 2026 for Nereus US approval (capitalized/prepaid).
• Salesforce: Nereus promotion via DTC (nereus.us) and existing Salesforce commenced Q3 2026.